I
Insulin Glargine
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
Yes
Subsidy Information and Financing Scheme
Standard Drug List
Active ingredient: Insulin Glargine
General information
Subsidy Information and Financing Scheme
[SDL] Insulin Glargine (Lantus) Injection 100 international units/mL
[SDL] Insulin Glargine (Lantus) Injection, Prefilled Pen 100 international units/mL
Drug Guidance for Subsidy
01/04/2022 High-strength insulin glargine for treating type 1 and 2 diabetes mellitus
[NR] The Ministry of Health’s Drug Advisory Committee has not recommended listing insulin glargine 300 units/ml on the Standard Drug List (SDL) for treating type 1 and 2 diabetes mellitus in view of unfavourable cost-effectiveness compared with insulin glargine 100 units/ml at the price proposed by the manufacturer, and low clinical need.
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Lantus Injection 100 international units/mL |
|
Lantus Injection, Prefilled Pen 100 international units/mL |
|
Toujeo Injection, Solution 300 units/mL |
|